Worth the Work with Jason Dana Costa

Worth the Work with Jason Dana Costa explores what it really takes to build organizations that matter.

Hosted by healthcare executive, consultant, and mission-driven leader Jason Costa, each episode features honest conversations with CEOs, nonprofit executives, healthcare innovators, and community leaders who are tackling meaningful challenges with curiosity, trust, and operational excellence.

From leadership and organizational strategy to healthcare innovation, culture, financial sustainability, and navigating complex change, Jason uncovers the lessons that don't make it into business books. These are conversations about building organizations that create lasting impact, earning trust when it matters most, and doing work that's truly worth the work.

Whether you're leading a healthcare organization, nonprofit, business, or growing team, you'll walk away with practical insights, fresh perspectives, and the inspiration to lead with purpose.

Contributors

Host

Jason Dana Costa

Jason Dana Costa, MBA, PHR, is the CEO of Horizon Pharmacy, Founder of JDC Strategies, and host of Worth the Work. With nearly 30 years of executive leadership experience across healthcare, behavioral health, education, and nonprofit organizations, Jason has built his career helping mission-driven organizations grow stronger and more sustainable. Through Worth the Work, he explores the leadership lessons, defining moments, and real-world experiences that shape meaningful careers, stronger organizations, and work truly worth doing.

Guests

Guest

David Esposito

David Esposito is the Chief Executive Officer of ONL Therapeutics, an early-stage biotechnology company developing therapies for retinal disease. A West Point graduate, combat veteran, and experienced healthcare executive, David has spent more than 30 years leading organizations through growth, acquisitions, turnarounds, restructurings, and difficult wind-downs. His career includes serving as CEO of Armune BioScience, which was acquired by Exact Sciences, and President of Phadia US/AB, which was acquired by Thermo Fisher Scientific.

Today, he brings those experiences to ONL Therapeutics, where the company's vision is to help patients "see the future."

Guest appearance on:

David Esposito - Chief Executive Officer, ONL Therapeutics